Fluoxymesterone Dosage
This dosage information may not include all the information needed to use Fluoxymesterone safely and effectively. See additional information for Fluoxymesterone.
The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.
Usual Adult Dose for:
Usual Pediatric Dose for:
Additional dosage information:
Usual Adult Dose for Hypogonadism - Male
5 to 20 mg orally once a day or divided into 3 or 4 doses. It is usually preferable to begin treatment with full therapeutic doses which should later be adjusted to individual requirements.
Usual Adult Dose for Breast Cancer
10 to 40 mg orally per day divided into 3 or 4 doses. The duration of therapy is at least one month for a satisfactory response, and 2 to 3 months for an objective response. Females with disseminated breast carcinoma should have frequent determination of the urine and serum calcium levels during the course of therapy. Female patients should also be observed for signs of virilization which is usual following androgen use at high doses. They may be instructed to report any hoarseness, acne, changes in menstrual periods or increase in facial hair. Discontinuation of drug therapy at the time of evidence of mild virilism is necessary to prevent irreversible virilization. A decision may be made that some virilization will be tolerated during the treatment for malignant disease.
Usual Adult Dose for Postmenopausal Symptoms
1 to 2 mg orally 2 times a day for 3 to 6 weeks. Fluoxymesterone is generally administered in combination with ethinyl estradiol.
Usual Pediatric Dose for Delayed Puberty - Male
2.5 to 20 mg orally per day or in 3 to 4 divided doses for up to 4 to 6 months. Dosage should be carefully titrated utilizing a low dosage.
Renal Dose Adjustments
Data not available
Liver Dose Adjustments
Data not available
Dose Adjustments
Dosage may depend on specific malignancy and whether other cytotoxic agents are coadministered. Reference to specific protocols is recommended.
Precautions
Patients with benign prostatic hypertrophy may develop acute urethral obstruction. Priapism or excessive sexual stimulation may develop. Patients should be instructed to report too frequent or persistent erections of the penis. Priapism is indicative of excessive doses and the need to temporarily discontinue fluoxymesterone therapy. Oligospermia may occur after prolonged administration or excessive dosage. If any of these effects appear, the androgen should be stopped and if restarted, a lower dosage should be utilized. Patients should be instructed to report any of the following: nausea, vomiting, changes in skin color, and ankle swelling. Because of the hepatotoxicity associated with the use of 17-alpha-alkylated androgens, liver function tests should be obtained periodically. Hemoglobin and hematocrit levels (to detect polycythemia) should be checked periodically with long-term administration. Fluoxymesterone is contraindicated in males with carcinoma of the breast.
Dialysis
Data not available
Other Comments
Exogenous androgen therapy can accelerate bone maturation without producing compensatory gain in linear growth. Use over long periods may result in fusion of the epiphyseal growth centers and termination of the growth process. The effects on bone maturation should be monitored by assessing the bone age of the wrist and hand every 6 months.
